Stockscreener 앱 받기
11.61
0.77%
-0.09
시간 외 거래:
11.40
-0.21
-1.81%
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.4%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
When (EYPT) Moves Investors should Listen - Stock Traders Daily
EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times
EyePoint Pharmaceuticals prices $140M share offering - MSN
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN
Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat
EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
EyePoint shares hold as analyst reiterates Buy rating By Investing.com - Investing.com South Africa
EyePoint reports positive DURAVYU trial results for DME By Investing.com - Investing.com South Africa
EyePoint launches $100 million public stock offering - Investing.com India
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
Guggenheim maintains Buy on EyePoint with $68 target By Investing.com - Investing.com UK
EyePoint reports positive DURAVYU trial results for DME - Investing.com India
EyePoint shares hold as analyst reiterates Buy rating - Investing.com
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss - Yahoo Finance
EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu - MarketWatch
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - The Manila Times
EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside - Investing.com Canada
EyePoint announces $175 million stock offering following record surge in share price - MSN
Analyst Ratings For EyePoint Pharmaceuticals - Benzinga
EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (NASDAQ:EYPT) Given Buy Rating at HC Wainwright - MarketBeat
SG Americas Securities LLC Sells 56,985 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint begins Phase 3 trial for wet AMD treatment By Investing.com - Investing.com Australia
Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals - Investing.com
Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals By Investing.com - Investing.com Canada
Alphabet Cl A (GOOGL-Q) QuotePress Release - The Globe and Mail
EyePoint begins Phase 3 trial for wet AMD treatment - Investing.com
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - StockTitan
AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2 - Pharmaceutical Technology
(EYPT) Investment Analysis and Advice - Stock Traders Daily
2.02%
0.47%
자본화:
|
볼륨(24시간):